Artificial intelligence has dominated investor attention for two years, but biotech revenue lines are also bending sharply ...
After several quarters on a steady sales roll as the world’s first treatment for metabolic dysfunction-associated steatohepatitis (MASH), the pressure is on for Madrigal Pharmaceuticals’ Rezdiffra ...
These companies boast significant upside potential.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results